2020 Volume 11 Issue 2 Pages 124-127
Daptomycin (DAP) is an antibiotic used to treat methicillin-resistant Staphylococcus aureus. The recommended dosage for patients undergoing continuous renal replacement therapy (CRRT) is 6-8mg/kg every 24-48h in Europe and the US. However, it is assumed that the pharmacokinetics in the Japanese CRRT setting is different, and thus, we examined the pharmacokinetics of DAP in four patients. The DAP dosage was 7.1 (IQR: 5.8-8.1) mg/kg every 48h. The modality for CRRT was continuous hemodiafiltration in two patients and continuous hemodialysis in two patients. The elimination half-life（t1/2）, area under the drug concentration-time curve (AUC), and minimum concentration (Cmin) were 20.7（19.5-20.6）h, 904 (525-1,281) mg・h/L, and 10.2 (8.2-10.5) mg/L, respectively. The t1/2 values were longer in this study than that reported in previous studies. With presumed minimum inhibitory concentration (MIC), AUC/MIC values achieved the efficacy target and Cmin values were low within the safety target. The dosage of DAP in patients undergoing CRRT is recommended as ＞6mg/kg every 48h, although clinical validation for the dosage is required.
